(Q51565999)

English

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

scientific article published on 13 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

author name string

Emilio Esteban Gonzalez

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Noemi Villanueva

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Joaquin Fra

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Jose Pablo Berros

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Paula Jimenez

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

María Luque

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Isabel Muñiz

7

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Pilar Blay

8

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Yolanda Fernandez

9

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

José María Vieitez

10

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Carolina Muriel

11

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Miguel Sanmamed

12

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Pablo Pardo Coto

13

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Marta Izquierdo

14

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Enrique Estrada

15

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Angel J Lacave

16

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

publication date

13 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

29

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

1459-1464

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

https://scigraph.springernature.com/pub.10.1007/s10637-010-9442-2

0 references

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Topotecan as first-line therapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9442-2

21 January 2018

Topotecan: an important new drug in the management of ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oral topotecan in advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

https://pubmed.ncbi.nlm.nih.gov/20464446

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9442-2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/20464446

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51565999&oldid=1405996385"